ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement in Steroid-Refractory Acute GvHD at the ASH 2025 Annual …

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives ...

NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 2025

New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood ...

How One Couple Navigates Uncharted Territory with GVHD After A Bone Marrow Transplant

Together, Kevin and Jaqi face graft-versus-host disease (GVHD), a complication that can occur following a bone marrow ...

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting

Sofi-cel is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy currently under evaluation in a pivotal trial (T-RRex) for patients with relapsed or refractory (R/R) ...
Healio

Favorable outcomes after HCT for sickle cell disease can guide shared decision-making

Most people with sickle cell disease who undergo allogeneic hematopoietic cell transplantation achieve favorable long-term ...